Stefano BibbÃ²

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6244573/publications.pdf Version: 2024-02-01



STEEANO RIBRÃ2

#	Article	IF	CITATIONS
1	Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent <i>Clostridium difficile</i> infection. Alimentary Pharmacology and Therapeutics, 2015, 41, 835-843.	1.9	467
2	The involvement of gut microbiota in inflammatory bowel disease pathogenesis: Potential for therapy. , 2015, 149, 191-212.		139
3	Probiotics, fibre and herbal medicinal products for functional and inflammatory bowel disorders. British Journal of Pharmacology, 2017, 174, 1426-1449.	2.7	126
4	Systematic review: sprue-like enteropathy associated with olmesartan. Alimentary Pharmacology and Therapeutics, 2014, 40, 16-23.	1.9	117
5	Reorganisation of faecal microbiota transplant services during the COVID-19 pandemic. Gut, 2020, 69, 1555-1563.	6.1	110
6	Gut microbiota modulation: probiotics, antibiotics or fecal microbiota transplantation?. Internal and Emergency Medicine, 2014, 9, 365-373.	1.0	98
7	The Effect of Lactobacillus reuteri Supplementation in Adults with Chronic Functional Constipation: a Randomized, Double-Blind, Placebo-Controlled Trial*. Journal of Gastrointestinal and Liver Diseases, 2020, 23, 387-391.	0.5	97
8	Fecal Microbiota Transplantation in Inflammatory Bowel Disease. Medicine (United States), 2014, 93, e97.	0.4	77
9	Therapeutic Modulation of Gut Microbiota: Current Clinical Applications and Future Perspectives. Current Drug Targets, 2014, 15, 762-770.	1.0	74
10	Is there a role for gut microbiota in type 1 diabetes pathogenesis?. Annals of Medicine, 2017, 49, 11-22.	1.5	73
11	Fecal Microbiota Transplantation: Screening and Selection to Choose the Optimal Donor. Journal of Clinical Medicine, 2020, 9, 1757.	1.0	65
12	Gut Microbiota as a Driver of Inflammation in Nonalcoholic Fatty Liver Disease. Mediators of Inflammation, 2018, 2018, 1-7.	1.4	62
13	Predictors of failure after single faecal microbiota transplantation in patients with recurrent Clostridium difficile infection: results from a 3-year, single-centre cohort study. Clinical Microbiology and Infection, 2017, 23, 337.e1-337.e3.	2.8	60
14	Gut microbiota alteration and modulation in psychiatric disorders: Current evidence on fecal microbiota transplantation. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 109, 110258.	2.5	52
15	Chronic autoimmune disorders are increased in coeliac disease. Medicine (United States), 2017, 96, e8562.	0.4	51
16	Role of Microbiota and Innate Immunity in Recurrent <i>Clostridium difficile</i> Infection. Journal of Immunology Research, 2014, 2014, 1-8.	0.9	43
17	Gastrointestinal involvement of autism spectrum disorder: focus on gut microbiota. Expert Review of Gastroenterology and Hepatology, 2021, 15, 599-622.	1.4	41
18	COVID-19 and intestinal inflammation: Role of fecal calprotectin. Digestive and Liver Disease, 2020, 52, 1231-1233.	0.4	40

 ${\sf Stefano}\;{\sf Bibb}\tilde{A}^2$

#	Article	IF	CITATIONS
19	Culture-guided treatment approach for <i>Helicobacter pylori</i> infection: Review of the literature. World Journal of Gastroenterology, 2014, 20, 5205.	1.4	38
20	COVID-19 as a trigger of irritable bowel syndrome: A review of potential mechanisms. World Journal of Gastroenterology, 2021, 27, 7433-7445.	1.4	37
21	Assessment of neurological manifestations in hospitalized patients with COVIDâ€19. European Journal of Neurology, 2020, 27, 2322-2328.	1.7	36
22	Fecal Microbiota Transplantation. Journal of Clinical Gastroenterology, 2014, 48, S80-S84.	1.1	33
23	Side Effects Associated with Probiotic Use in Adult Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Nutrients, 2019, 11, 2913.	1.7	32
24	Fecal transplantation for ulcerative colitis: current evidence and future applications. Expert Opinion on Biological Therapy, 2020, 20, 343-351.	1.4	29
25	Role of Probiotics in <i>Helicobacter pylori</i> Eradication: Lessons from a Study of <i>Lactobacillus reuteri</i> Strains DSM 17938 and ATCC PTA 6475 (Gastrus®) and a Proton-Pump Inhibitor. Canadian Journal of Infectious Diseases and Medical Microbiology, 2019, 2019, 1-8.	0.7	25
26	Constipation in the elderly from Northern Sardinia is positively associated with depression, malnutrition and female gender. Scandinavian Journal of Gastroenterology, 2018, 53, 797-802.	0.6	23
27	Fecal microbiota transplantation: past, present and future perspectives. Minerva Gastroenterology, 2017, 63, 420-430.	0.3	22
28	Fecal microbiota transplantation for recurrent C. difficile infection in patients with inflammatory bowel disease: experience of a large-volume European FMT center. Gut Microbes, 2021, 13, 1994834.	4.3	21
29	Fecal Microbiota Signatures in Celiac Disease Patients With Poly-Autoimmunity. Frontiers in Cellular and Infection Microbiology, 2020, 10, 349.	1.8	20
30	Prior Misdiagnosis of Celiac Disease Is Common Among Patients Referred to a Tertiary Care Center: A Prospective Cohort Study. Clinical and Translational Gastroenterology, 2016, 7, e139.	1.3	19
31	Direct effect of infliximab on intestinal mucosa sustains mucosal healing: exploring new mechanisms of action. Digestive and Liver Disease, 2016, 48, 391-398.	0.4	17
32	Twiceâ€aâ€day PPI, tetracycline, metronidazole quadruple therapy with Pylera® or L a ctobacillus reuteri for treatment naÃ⊤ve or for retreatment of Helicobacter pylori . Two randomized pilot studies. Helicobacter, 2019, 24, e12659.	1.6	17
33	Maintaining standard volumes, efficacy and safety, of fecal microbiota transplantation for C. difficile infection during the COVID-19 pandemic: A prospective cohort study. Digestive and Liver Disease, 2020, 52, 1390-1395.	0.4	16
34	Letter: telmisartan associated enteropathy – is there any class effect? Authors' reply. Alimentary Pharmacology and Therapeutics, 2014, 40, 570-570.	1.9	15
35	Inclusion of Lactobacillus Reuteri in the Treatment of Helicobacter pylori in Sardinian Patients. Medicine (United States), 2016, 95, e3411.	0.4	15
36	Risk of burnout and stress in physicians working in a COVID team: A longitudinal survey. International Journal of Clinical Practice, 2021, 75, e14755.	0.8	13

 ${\sf Stefano}\;{\sf Bibb}\tilde{A}^2$

#	Article	IF	CITATIONS
37	Role of gut microbiome on immunotherapy efficacy in melanoma. Human Vaccines and Immunotherapeutics, 2022, 18, 1-6.	1.4	12
38	Current technologies for the endoscopic assessment of duodenal villous pattern in celiac disease. Computers in Biology and Medicine, 2015, 65, 308-314.	3.9	11
39	Coeliac disease: beyond genetic susceptibility and gluten. A narrative review. Annals of Medicine, 2019, 51, 1-16.	1.5	11
40	Microbiome: what intensivists should know. Minerva Anestesiologica, 2020, 86, 777-785.	0.6	11
41	Donor program for fecal microbiota transplantation: A 3-year experience of a large-volume Italian stool bank. Digestive and Liver Disease, 2021, 53, 1428-1432.	0.4	10
42	Letter: prevalence and patterns of gastrointestinal symptoms in a large Western cohort of patients with COVID-19. Alimentary Pharmacology and Therapeutics, 2020, 52, 902-903.	1.9	9
43	Clinical features and natural history of idiopathic peptic ulcers: a retrospective case–control study. Scandinavian Journal of Gastroenterology, 2019, 54, 1315-1321.	0.6	8
44	Fecal microbiota transplant for C.Âdifficile infection: Just say yes. Anaerobe, 2019, 60, 102109.	1.0	8
45	Tu1363 An Open-Label, Pilot Study to Assess Feasibility and Safety of Fecal Microbiota Transplantation in Patients With Mild-Moderate Ulcerative Colitis: Preliminary Results. Gastroenterology, 2015, 148, S-870.	0.6	7
46	Cancer time trend in a population following a socio-economic transition: results of age-period-cohort analysis. International Journal of Public Health, 2017, 62, 407-414.	1.0	7
47	Risk Factors, Diagnosis, and Management of Clostridioides difficile Infection in Patients with Inflammatory Bowel Disease. Microorganisms, 2022, 10, 1315.	1.6	7
48	Barrett's oesophagus and associated dysplasia are not equally distributed within the esophageal circumference. Digestive and Liver Disease, 2016, 48, 1043-1047.	0.4	6
49	Impact of SARS-CoV-2 Infection on the Course of Inflammatory Bowel Disease in Patients Treated with Biological Therapeutic Agents: A Case-Control Study. Biomedicines, 2022, 10, 843.	1.4	6
50	Metagenomic Changes of Gut Microbiota following Treatment of Helicobacter pylori Infection with a Simplified Low-Dose Quadruple Therapy with Bismuth or Lactobacillus reuteri. Nutrients, 2022, 14, 2789.	1.7	6
51	Response to: Comment on "Gut Microbiota as a Driver of Inflammation in Nonalcoholic Fatty Liver Disease― Mediators of Inflammation, 2018, 2018, 1-2.	1.4	5
52	Increased Frequency of Immune Thrombocytopenic Purpura in Coeliac Disease and Vice Versa: A Prospective Observational Study. Gastroenterology Research and Practice, 2018, 2018, 1-4.	0.7	5
53	SARS-CoV-2 vaccines and donor recruitment for FMT. The Lancet Gastroenterology and Hepatology, 2021, 6, 264-266.	3.7	5
54	Reactive arthritis secondary to <i>Hafnia alvei</i> enterocolitis. BMJ Case Reports, 2019, 12, e228513.	0.2	4

 ${\sf Stefano}\;{\sf Bibb}\tilde{A}^2$

#	Article	IF	CITATIONS
55	The impact of COVID-19 pandemic on IBD endoscopic procedures in a high-volume IBD Center. Endoscopy International Open, 2020, 08, E980-E984.	0.9	4
56	Oral supplementation with lactobacilli to prevent colorectal cancer in preclinical models. Minerva Gastroenterologica E Dietologica, 2020, 66, 48-69.	2.2	3
57	High Frequency of Glucose-6-Phosphate Dehydrogenase Deficiency in Patients Diagnosed with Celiac Disease. Nutrients, 2022, 14, 1815.	1.7	3
58	The Rise and Fall of the Secular Trend in Body Height in Sardinia: An Age-Period-Cohort Analysis. Biomedical and Environmental Sciences, 2020, 33, 183-190.	0.2	1
59	OC.11.3 MUCOSAL HEALING DOES NOT CORRESPOND TO HISTOLOGICAL HEALING IN ULCERATIVE COLITIS. Digestive and Liver Disease, 2014, 46, S26-S27.	0.4	0
60	OC.16.4 DIRECT ROLE OF INFLIXIMAB ON INTESTINAL MUCOSA SUSTAINS MUCOSAL HEALING: EXPLORING NEW MECHANISMS OF ACTION. Digestive and Liver Disease, 2014, 46, S35.	0.4	0
61	Tu1533 Esophageal Posterior and Right Wall Are the Most Common Localizations of Barrett's Esophagus. Gastrointestinal Endoscopy, 2015, 81, AB499.	0.5	0
62	Sa1301 High Rates of Prior Celiac Disease Overdiagnosis Among Patients Referring to an Italian Tertiary Care Center. Gastroenterology, 2015, 148, S-286.	0.6	0
63	P.12.2 DIAGNOSIS OF CELIAC DISEASE IN ADULTS WITHOUT DUODENAL BIOPSY IN THE PRESENCE OF POSITIVE ANTI-ENDOMYSIUM ANTIBODIES AND ANTI-TRANSGLUTAMINASE ANTIBODIES. Digestive and Liver Disease, 2016, 48, e185.	0.4	0
64	P.08.11 THE POSITION WITHIN THE OESOPHAGEAL CIRCUMFERENCE PREDICTS DYSPLASIA IN SHORT SEGMENT BARRETT'S ESOPHAGUS: A 7-YEAR RETROSPECTIVE SERIES OF 341 LESIONS. Digestive and Liver Disease, 2016, 48, e168-e169.	0.4	0
65	OC.12.9 FECAL MICROBIOTA TRANSPLANTATION FOR RECURRENT C. DIFFICILE INFECTION: A 2-YEAR EXPERIENCE FROM A EUROPEAN REFERRAL CENTRE. Digestive and Liver Disease, 2016, 48, e118.	0.4	0
66	Tu1319 - Lactobacillus Reuteri and a PPI Alone Provide Approximately a 12% Additive Increase in H. Pylori Eradication. Gastroenterology, 2018, 154, S-932.	0.6	0
67	Pasta made with sorghum flour is a valid alternative in the gluten-free diet, reducing metabolic disorders and nutritional deficiencies. Digestive and Liver Disease, 2021, 53, 1527-1528.	0.4	0